Each year, The Leukemia & Lymphoma Society of Canada forms a group of medical experts with the task of reviewing research projects taking place in Canada that show the greatest promise in advancing our understanding of different blood cancers, ability to test therapies and ultimately, to find cures.
Once a year, our Scientific Review Panel selects research projects led by established and new scientists working in various cancer centres across Canada.
Our Operating Grants offer funding (up to $100,000/year) for two-years for basic research that contributes to the advancement of science aimed at preventing, detecting and treating blood cancers. These grants recognize scientists whose work will contribute to the tremendous momentum in blood cancer research and yield groundbreaking results in treating patients and extending lives.
Canadian Blood Cancer Researchers, new and established, are invited to submit proposals for The Leukemia & Lymphoma Society of Canada (LLSC) Operating Grants.
2020 Grants Competition
Open September 4, 2019
The application process will occur in two phases. The first phase is submission and consideration of a Letter of Intent (LOI). The second phase is the invitation for and submission of a Full Application. The applicant must register with the LLSC Research Portal, Proposal Central in order to apply. Both the LOI and the Full Application must be submitted electronically to Proposal Central.
Applicants must carefully read the program guidelines before beginning their applications;
2019 - 2020 Application Key Dates
|Call for Proposals||September 4, 2019|
|Letter of Intent (LOI) due||October 25, 2019, 3:00 pm (EST)|
|Notification of Full Application Invite||November 2019|
|Full application deadline||February 5, 2020, 3:00 pm EST|
|Review Panel Meeting||April 2020|
|Notification of Awards||May 2020|
|Award Start Date||July 2020|
Funds for competitive applications will be awarded on the basis of scientific merit, using a priority rating system.
Submitting a Letter of Intent is mandatory for all applicants.